Synaptic vesicle protein 2A predicts response to levetiracetam in patients with glioma
Synaptic vesicle protein 2A predicts response to levetiracetam in patients with glioma
复制标题
DOI：
10.1212/wnl.0b013e318228c110
复制
发表时间：
2011-08-01
期刊：
影响因子：
9.9
通讯作者：
Reijneveld, J. C.
中科院分区：
文献类型：
--
作者：
de Groot, M.;Aronica, E.;Reijneveld, J. C.
目的：在前瞻性队列中将癫痫胶质瘤患者手术切除的肿瘤和瘤周组织中的 SV2A 表达与左乙拉西坦的临床反应相关联。方法：招募了 40 名癫痫胶质瘤患者。所有患者均接受了手术并接受左乙拉西坦单药治疗。记录临床特征。随访安排在 3 个月和 6 个月。对左乙拉西坦有反应的患者与无反应的患者进行比较。通过免疫组织化学方法测定手术切除的肿瘤和瘤周组织中SV2A的表达。使用光密度 (OD) 来测量 SV2A 表达。结果：总共 34 名患者符合分析条件。与没有表现出这种反应的患者（平均 8.1，SD 7.7，p < 0.01 和 45.6，SD 11.2，p < 0.01）相比，对治疗有良好反应的患者具有显着更强的 SV2A 表达，如肿瘤组织（平均 44.5，SD 17.3）以及瘤周组织（平均 67.5，SD 7.8）中的 OD 所示。 SV2A 表达预测左乙拉西坦单药治疗的疗效，准确度为 91%。结论：我们的结果表明，肿瘤和瘤周组织中 SV2A 的表达与左乙拉西坦的临床反应相关，并预测左乙拉西坦疗效。神经病学（R）2011；77：532-539
Objectives: To correlate SV2A expression in surgically removed tumor and peritumoral tissue of glioma patients with epilepsy with the clinical response to levetiracetam in a prospective cohort.Methods: Forty glioma patients with epilepsy were recruited. All patients had undergone surgery and were on levetiracetam monotherapy. Clinical characteristics were documented. Follow-up visits were scheduled at 3 and 6 months. Patients who responded to levetiracetam were compared to those who did not respond. Expression of SV2A was determined by means of immunohistochemistry in the surgically removed tumor and peritumoral tissue. Optical density (OD) was used to measure SV2A expression.Results: In total, 34 patients were eligible for analysis. Patients with a good response to treatment had significantly stronger SV2A expression as demonstrated by OD in tumor tissue (mean 44.5, SD 17.3) as well as in peritumoral tissue (mean 67.5, SD 7.8) than patients who did not show such a response (mean 8.1, SD 7.7, p < 0.01 and 45.6, SD 11.2, p < 0.01). SV2A expression predicted efficacy of levetiracetam monotherapy with an accuracy of 91%.Conclusions: Our results suggest that expression of SV2A in tumor and peritumoral tissue is correlated to the clinical response to levetiracetam and predicts levetiracetam efficacy. Neurology (R) 2011;77:532-539